Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 7/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27817372 | 0.70 | CYP3A4 (0.33) | KDM4EALDH1A1HPGDNPSR1GAA | |
| SCHEMBL14837406 | 0.66 | PARP1 (0.52) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL918282 | 0.65 | HTR2C (0.37) | KDM4EALDH1A1L3MBTL1TSHR | |
| SCHEMBL27817301 | 0.65 | KDM4E (0.40) | KDM4EALDH1A1HPGDHTTNPC1 | |
| SCHEMBL2673088 | 0.64 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDTDP1NPSR1 | |
| SCHEMBL1133289 | 0.62 | MGAM (0.47) | KDM4EALDH1A1HPGDTDP1NPSR1 | |
| SCHEMBL6256897 | 0.61 | KDM4E (1.00) | KDM4EALDH1A1HPGDNPSR1L3MBTL1 | |
| SCHEMBL28164659 | 0.61 | RPS6KB2 (0.51) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL7013904 | 0.61 | KDM4E (0.58) | KDM4EALDH1A1HPGDTDP1NPSR1 | |
| SCHEMBL3972213 | 0.61 | BRD4 (0.52) | KDM4EALDH1A1TDP1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| EP-1758864-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123687-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885ALDH1A1 234/4885HPGD 71/4885 |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885ALDH1A1 234/4885HPGD 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.